source
- Eyepoint's wet AMD therapy misses primary goal in Phase 3, stock tumblesEyepoint reported that its experimental drug Duravyu did not keep vision in patients with wet age-related macular degeneration when given less frequently than the standard of care, causing the Phas…
- EyePoint shares tumble as Durayvu misses primary goal in wet AMD trialEyePoint, a Boston biotech, saw its market value drop by nearly $1 billion after its lead candidate Durayvu failed to demonstrate non-inferiority to aflibercept in a pivotal phase 3 trial for wet a…